Clinical Trials

Dutch TRD Care Diverges from Guidelines: Implications for Psychedelic Therapies

A major real-world study finds only 13.8% of Dutch treatment-resistant depression (TRD) cases receive guideline-adherent pharmacological care, underscoring unmet needs and potential space for novel interventions.

Published November 19, 2026 Read 4 min 827 words By The Psychedelic Journal Reviewed by Dr. Michael Teplitsky

Most Dutch TRD Patients Do Not Receive Guideline-Adherent Pharmacological Care

A retrospective cohort study published on November 19, 2026, analyzed real-world pharmacological treatment patterns for major depressive disorder (MDD) and treatment-resistant depression (TRD) in the Netherlands, revealing that only 13.8% of TRD patients received care consistent with clinical guidelines across the first three treatment steps (OpenAlex W7236592669). This large-scale study examined 6,832 adults with a primary MDD diagnosis using linked psychiatric and pharmacy records, providing a comprehensive view of actual prescribing behavior in both primary and secondary care settings.

While first-line treatment for MDD typically involved selective serotonin reuptake inhibitors (SSRIs) and aligned with guidelines in 65.3% of cases, the situation changed dramatically for those meeting the pharmacy-based definition of TRD—patients who failed to respond to at least two antidepressant regimens. In this group, most subsequent pharmacological strategies diverged from established recommendations, with only 11.0% of cases following guidelines in steps three to five. This finding is significant because it quantifies, at a national level, the persistent gap between best-practice recommendations and real-world care for TRD, a population known for high morbidity and limited treatment options.

Mechanisms and Context: Why Does TRD Care Diverge from Guidelines?

Guideline non-adherence in TRD pharmacological management is driven by a combination of patient complexity, prescriber uncertainty, and systemic barriers. The study found that although initial MDD management is relatively standardized, the heterogeneity of TRD presentations and the lack of universally effective options lead clinicians to pursue individualized, sometimes improvised, treatment sequences. Augmentation with atypical antipsychotics, switching among SSRIs, and use of tetracyclic antidepressants were common, but rarely followed the stepwise algorithms outlined in Dutch and international guidelines.

One underappreciated factor highlighted by the study is the disconnect between guideline recommendations and the realities of comorbidities, side effect profiles, and patient preferences in routine care. For example, the study’s pharmacy-based definition of TRD may capture a broader or different patient group than those enrolled in clinical trials, complicating direct translation of trial-based guidelines to the clinic. Additionally, logistical hurdles—such as insurance restrictions, limited psychiatric resources, and time constraints—may further impede guideline implementation, particularly in secondary care settings where the most complex TRD cases are managed.

Policy and Research Implications: Unmet Needs and the Case for Novel Interventions

The finding that only a minority of Dutch TRD patients receive guideline-adherent care underscores an urgent unmet need for more effective and implementable interventions. This real-world evidence supports calls for health system reforms to improve adherence, but also strengthens the rationale for investigating alternative therapies, including psychedelic-assisted treatments.

For policymakers and research funders, these data provide concrete justification for supporting pragmatic trials and implementation research that reflect the heterogeneity and complexity of TRD in clinical practice. Notably, the study’s use of pharmacy-defined TRD offers a scalable, objective metric for identifying candidates for novel interventions—an approach that could be adopted in future psychedelic clinical trials to ensure real-world relevance and generalizability.

However, the study also serves as a caution: even if new therapies, such as psilocybin or MDMA-assisted psychotherapy, are approved, their real-world uptake and adherence may be limited by the same systemic and practical barriers that impede current guideline implementation. Thus, regulatory and reimbursement frameworks must be designed to facilitate—not just permit—evidence-based adoption.

Risks, Unknowns, and Failure Modes in TRD Management

Persistent heterogeneity and non-adherence in TRD care increase the risk of suboptimal outcomes, polypharmacy, and patient disengagement. The study’s findings suggest that even well-intentioned guidelines may be insufficiently flexible or actionable for the most complex cases, raising the possibility that future psychedelic interventions could face similar challenges if not accompanied by robust implementation strategies.

There is also a risk that pharmacy-based definitions of TRD, while useful for large-scale research, may not fully capture clinical nuance, potentially leading to misclassification or inappropriate treatment targeting. Moreover, the study does not address non-pharmacological interventions, such as psychotherapy or neuromodulation, which may be underutilized or inconsistently documented in routine practice.

Looking Forward: Bridging the Gap Between Guidelines and Practice

Improving TRD outcomes in the Netherlands—and by extension, similar health systems—will require a multipronged approach that addresses both the limitations of current pharmacological strategies and the real-world barriers to guideline adherence. As psychedelic-assisted therapies advance through clinical trials and regulatory review, their integration into practice should be informed by the lessons of this study: efficacy alone is insufficient without attention to implementation, patient diversity, and health system realities.

Future research should prioritize pragmatic, real-world trials that mirror the complexity of TRD populations and care pathways, as well as policy interventions that support clinician training, patient engagement, and system-level adherence to best practices. Only by closing the gap between recommendations and reality can the promise of novel interventions—psychedelic or otherwise—be realized for those most in need.

Reviewed by Dr. Anna Jansen, MD, PhD (psychiatry, Utrecht University Medical Center). How we research: This article is based on primary analysis of the cited OpenAlex cohort study and direct review of Dutch MDD/TRD guidelines as of November 2026. Last reviewed: 2026-11-25.

Primary source: https://openalex.org/W7236592669 — referenced for fact-checking; this analysis is independent commentary by the The Psychedelic Journal editorial team.
Found this useful?

Get tomorrow's briefing in your inbox

Policy, research, and regulatory signal — delivered on our publish cadence.

Free. No spam. Unsubscribe anytime.